Neuregulin 4 attenuates pancreatic β-cell apoptosis induced by lipotoxicity via activating mTOR-mediated autophagy

Biao Zhu1, Lei Sun2, Junyao Tong3

  • 1Department of Stomatology, Fuxing Hospital, Capital Medical University, Beijing, China.

Islets
|November 14, 2024
PubMed

Insights

Neuregulin 4 (Nrg4) protects pancreatic beta cells from lipotoxicity-induced apoptosis by enhancing autophagy. This process involves the mammalian target of rapamycin (mTOR) pathway, suggesting Nrg4 as a potential therapy for type 2 diabetes.

Area of Science:

  • Endocrinology
  • Cell Biology
  • Metabolic Disorders

Background:

  • Neuregulin 4 (Nrg4) is an endocrine factor that improves lipid metabolism.
  • Autophagy is crucial for pancreatic beta-cell survival against lipotoxicity.
  • Lipotoxicity contributes to beta-cell dysfunction and apoptosis in type 2 diabetes.

Purpose of the Study:

  • To investigate if Nrg4 can prevent lipotoxicity-induced apoptosis in pancreatic beta cells by regulating autophagy.
  • To explore the underlying molecular mechanisms, including the role of the mammalian target of rapamycin (mTOR) pathway.

Main Methods:

  • Mouse pancreatic beta-cell line (MIN6) was treated with palmitic acid (PA) and Nrg4.
  • Apoptosis rates and levels of apoptosis-related proteins (Bcl-2, Bax, cleaved-caspase 3) were measured.
  • Autophagic flux, autophagy-related proteins, and mTOR signaling pathway activity were evaluated.

Main Results:

  • Nrg4 significantly reduced PA-induced MIN6 cell apoptosis.
  • Nrg4 treatment increased anti-apoptotic Bcl-2 and decreased pro-apoptotic Bax and cleaved-caspase 3.
  • Nrg4 reactivated autophagy suppressed by PA, acting through the mTOR signaling pathway.
  • Inhibition of mTOR or autophagy abolished the protective effects of Nrg4.

Conclusions:

  • Nrg4 administration attenuates lipotoxicity-induced pancreatic beta-cell apoptosis.
  • This protective effect is mediated by the promotion of mTOR-dependent autophagy.
  • Nrg4 shows potential as a novel therapeutic strategy for type 2 diabetes mellitus (T2DM).

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
Insulin Secretory Vesicles01:05

Insulin Secretory Vesicles

Insulin secretory vesicles release insulin to stimulate blood glucose uptake and regulate carbohydrate metabolism. When the blood glucose levels increase, glucose enters the pancreatic β-islet cells through glucose transporters. Once inside, glucose is metabolized through glycolysis, the citric acid cycle, and the electron transport chain, producing ATP. This increase in ATP concentration closes ATP-sensitive potassium channels, leading to depolarization of the membrane and the opening of...
4.8K
Glucose Homeostasis: Pancreatic Islets and Insulin Secretion01:27

Glucose Homeostasis: Pancreatic Islets and Insulin Secretion

The pancreatic islets comprising only 1%-2% of the volume are highly vascularized and innervated mini-organs. They contain five endocrine cell types, including β cells that secrete insulin, which is synthesized as a single polypeptide chain, preproinsulin, processed to proinsulin, and finally to insulin and C-peptide. This process is complex and regulated, involving the Golgi complex, the endoplasmic reticulum, and the secretory granules of the β cell.
Insulin and C-peptide are...
1.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
172
Autophagic Cell Death01:18

Autophagic Cell Death

Christian de Duve discovered “autophagy,” a process in which cellular components are engulfed by membrane-bound organelles called autophagosomes. The autophagosomes then fuse with lysosomes to digest the enclosed contents. Autophagy is generally activated in cells to prevent cell death. However, cell death is triggered when the damage is beyond repair.
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
3.4K